Exclusive: GSK revamps its research strategy, building three teams to target specific disease spaces
GSK is shaking up the way it does research and created three unique teams zeroing in on vaccines and infectious diseases, respiratory and immunology, and oncology. The changes went live Monday.
Kaivan Khavandi is rejoining GSK from BenevolentAI to lead the respiratory and immunology research team. Phil Dormitzer, GSK’s senior vice president and global head of vaccines R&D, will broaden his remit by also covering infectious diseases. And GSK’s senior vice president global head for oncology development, Hesham Abdullah, will stay on as the oncology lead.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.